Adipose-derived SVF for Treatment of Erectile Dysfunction (ED)

Withdrawn before enrolling · Not applicable

Conditions studied: Erectile Dysfunction

In brief

This study will examine the safety and feasibility of a single injection of autologous adipose-derived stromal vascular fraction to treat erectile dysfunction.

Key facts

Study ID

NCT03886402

Run by

GID BIO, Inc.

People needed

0

Starts

2021-10-01

Expected to finish

2022-10-01

Last updated by the study team

2025-04-24

Who can join

Age: 18 and older, up to 65. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• history of ED of at least 3 months' duration
• have been taking a Phosphodiesterase type 5 (PDE5) inhibitor for at least 1 month prior and willing to stop taking any PDE5 inhibitor for duration of study
• have an IIEF-EF domain score that is ≥11 and ≤25
• have the same sexual partner for the duration of the study
• subject and partner willing to voluntarily give consent
• speak, read and understand English

You may not qualify if…

• non-responders to PDE5 inhibitor
• radical prostatectomy or other pelvic surgery or penile implant
• currently taking blood thinners, cancer drugs or HIV drugs
• allergic to lidocaine, epinephrine, valium
• diminished decision-making capacity
• use of tobacco
• previous pelvic or abdominal radiation therapy
• anti-androgen therapy
• untreated hypogonadism
• uncontrolled hypertension or hypotension
• unstable cardiovascular disease
• systemic autoimmune disorder

Where it is running

• David Matthews MD — Charlotte, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.